Biggest News Aggregation in the World
๐Ÿ“ฐ Looking Statement News

Page 19 - Looking Statement News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.

Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) -October 21, 2023 at 08:46 am EDT

At a pre-specified interim analysis in LITESPARK-005, WELIREG reduced the risk of disease progression or death compared to everolimus First Phase 3 trial to show positive results in patients with...
United States Merck Co Inc Exchange Commission Statement Of Merck Co Inc European Society For Medical Oncology European Society

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

In the KEYNOTE-811 trial, the KEYTRUDA regimen demonstrated a statistically significant PFS improvement in advanced HER2-positive gastric or GEJ adenocarcinoma in tumors expressing PD-L1 compared to...
United States Yelenay Janjigian Merck Co Inc European Commission Exchange Commission Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1) -October 13, 2023 at 07:46 am EDT

Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE-859 trial If approved, a KEYTRUDA combination would become an option in the EU for the treatment of both...
United States Merck Co Inc European Union Statement Of Merck Co Inc Exchange Commission Merck Research Laboratories

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for...
United States Seagen Padcev Seagen Inc European Society For Medical Oncology Agensys Inc Merck Research Laboratories

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science